 |
市場調查報告書
商品編碼
1665102
遺傳檢測市場機會、成長動力、產業趨勢分析與 2025 - 2034 年預測Hereditary Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
||||||
2024 年全球遺傳檢測市場價值為 76 億美元，預計 2025 年至 2034 年期間將以 7.7% 的強勁複合年成長率成長。這項革命性的技術在識別遺傳疾病、早期診斷、評估風險因素和為個人制定個人化治療方案方面發揮著越來越重要的作用。市場的快速成長可歸因於基因組研究和技術的進步，這使得基因檢測變得更實惠且可供更廣泛的人使用。隨著遺傳檢測越來越深入融入日常醫療保健實踐，並得到政府優惠政策和日益增強的健康意識的支持，遺傳檢測的需求達到了前所未有的高度。
隨著個人化醫療的發展，遺傳檢測被定位為精準醫療的基石，幫助醫生根據基因資訊客製化治療方案。這一趨勢使得基因檢測在產前篩檢、疾病預測和癌症風險評估等不同領域的應用日益廣泛。這些應用正在改變現代醫療保健，強調了進行基因檢測以促進早期干預和改善長期健康結果的必要性。此外，人們對遺傳疾病的認知不斷提高，加上保險支持和報銷政策帶來的可及性提高，大大促進了市場的擴張。
| 市場範圍 | |
|---|---|
| 起始年份 | 2024 |
| 預測年份 | 2025-2034 |
| 起始值 | 76億美元 |
| 預測值 | 159億美元 |
| 複合年成長率 | 7.7％ |
根據疾病類型，市場分為遺傳性癌症檢測和遺傳性非癌症檢測。 2024年，遺傳性非癌症檢測佔據市場主導地位，創造55億美元的收入。需求激增是由於人們對遺傳疾病認知的提高以及早期檢測的重要性日益增加。患者和醫療保健提供者都更加重視主動的基因篩檢和諮詢，從而導致向預防性醫療保健策略的轉變。
從技術上講，市場分為細胞遺傳學、生化和分子檢測，其中分子檢測佔據最大的市場佔有率，到 2024 年將達到 54.1%。這些先進的技術能夠同時檢測多種基因變異，進而降低成本和周轉時間。此外，分子檢測平台中人工智慧和機器學習的整合正在簡化資料解釋、增強基因變異分類並進一步推動市場成長。
光是在美國，遺傳檢測市場規模在2024年就達到了22億美元，預計將維持上升趨勢。國內遺傳疾病和遺傳性癌症的發生率不斷上升，刺激了基因檢測服務的需求。保險覆蓋範圍的擴大和優惠的報銷政策使得基因檢測更加容易獲得，從而加速了其普及。隨著基因組研究的不斷進步和對個人化醫療的日益關注，遺傳檢測市場有望持續成長，並在改善全球健康狀況方面發揮關鍵作用。
目錄
第 1 章：方法論與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業衝擊力
- 成長動力
- 遺傳性疾病盛行率不斷上升
- 基因組技術的進步
- 個人化醫療需求不斷成長
- 非侵入性產前檢測的採用率不斷提高
- 產業陷阱與挑戰
- 高級基因檢測費用高昂
- 成長動力
- 成長潛力分析
- 監管格局
- 美國
- 歐洲
- 技術格局
- 未來市場趨勢
- 重要新聞和舉措
- 差距分析
- 波特的分析
- PESTEL 分析
第4章：競爭格局
- 介紹
- 公司市佔率分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 策略儀表板
第 5 章：市場估計與預測：按疾病類型，2021 – 2034 年
- 主要趨勢
- 遺傳性癌症檢測
- 肺癌
- 乳癌
- 大腸直腸癌
- 子宮頸癌
- 卵巢癌
- 攝護腺癌
- 胃癌
- 黑色素瘤
- 肉瘤
- 子宮癌
- 胰腺癌
- 其他遺傳性癌症
- 遺傳性非癌症檢測
- 基因檢測
- 心臟疾病
- 罕見疾病
- 其他疾病
- 植入前基因診斷與篩檢
- 非侵入性產前檢測 (NIPT) 和攜帶者篩檢測試
- 新生兒基因篩檢
- 基因檢測
第6章：市場估計與預測：按技術，2021 – 2034 年
- 主要趨勢
- 細胞遺傳學
- 生化
- 分子檢測
第 7 章：市場估計與預測：按地區，2021 年至 2034 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
第8章：公司簡介
- Agilent Technologies
- Centogene
- CooperSurgical
- F. Hoffmann-La Roche
- Fulgent Genetics
- Illumina
- Invitae Corporation
- Laboratory Corporation of America Holdings
- MedGenome
- Myriad Genetics
- Natera
- Quest Diagnostics
- Sophia Genetics
- Thermo Fisher Scientific
- Twist Bioscience
The Global Hereditary Testing Market, valued at USD 7.6 billion in 2024, is projected to grow at a robust CAGR of 7.7% from 2025 to 2034. Hereditary testing, often referred to as genetic testing, analyzes an individual's DNA to detect gene, chromosome, or protein mutations inherited from parents. This revolutionary technology plays an increasingly pivotal role in identifying genetic conditions, enabling early diagnoses, assessing risk factors, and tailoring personalized treatment plans for individuals. The market's rapid growth can be attributed to advancements in genomic research and technology, which have made genetic testing more affordable and accessible to a wider population. With greater integration into everyday healthcare practices and supported by favorable government policies and increasing health awareness, the demand for hereditary testing is at an all-time high.
As personalized medicine gains momentum, hereditary testing is positioned as a cornerstone of precision healthcare, helping doctors customize treatments based on genetic information. This trend has led to the growing use of genetic tests in diverse areas like prenatal screening, disease prediction, and cancer risk evaluation. These applications are transforming modern healthcare, emphasizing the need for genetic testing to facilitate early interventions and improve long-term health outcomes. Additionally, growing awareness of genetic conditions, combined with improved accessibility due to insurance support and reimbursement policies, has contributed significantly to the market's expansion.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $7.6 Billion |
| Forecast Value | $15.9 Billion |
| CAGR | 7.7% |
By disease type, the market is divided into hereditary cancer testing and hereditary non-cancer testing. In 2024, hereditary non-cancer testing dominated the market, generating USD 5.5 billion in revenue. This surge in demand is driven by increased awareness of genetic disorders and the growing importance of early detection. Patients and healthcare providers alike are placing more emphasis on proactive genetic screening and counseling, leading to a shift toward preventive healthcare strategies.
Technologically, the market is categorized into cytogenetic, biochemical, and molecular testing, with molecular testing holding the largest market share at 54.1% in 2024. This segment is expected to experience substantial growth during the forecast period, thanks to innovations like multiplex PCR assays that have improved testing accuracy and efficiency. These advanced technologies enable the simultaneous detection of multiple genetic variants, reducing both costs and turnaround times. Additionally, the integration of artificial intelligence and machine learning in molecular testing platforms is streamlining data interpretation, enhancing genetic variant classification, and further driving market growth.
In the U.S. alone, the hereditary testing market reached USD 2.2 billion in 2024 and is expected to maintain its upward trajectory. The rising prevalence of genetic disorders and hereditary cancers in the country is fueling the demand for genetic testing services. Enhanced insurance coverage and favorable reimbursement policies are making genetic testing more accessible, accelerating adoption. With ongoing advancements in genomic research and a growing focus on personalized medicine, the hereditary testing market is poised for continued growth, playing a crucial role in improving health outcomes worldwide.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Growing prevalence of hereditary diseases
- 3.2.1.2 Advancements in genomic technologies
- 3.2.1.3 Rising demand for personalized medicine
- 3.2.1.4 Increasing adoption of non-invasive prenatal testing
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High cost of advanced genetic tests
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Europe
- 3.5 Technology landscape
- 3.6 Future market trends
- 3.7 Key news and initiatives
- 3.8 Gap analysis
- 3.9 Porter’s analysis
- 3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 – 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Hereditary cancer testing
- 5.2.1 Lung cancer
- 5.2.2 Breast cancer
- 5.2.3 Colorectal cancer
- 5.2.4 Cervical cancer
- 5.2.5 Ovarian cancer
- 5.2.6 Prostate cancer
- 5.2.7 Stomach/gastric cancer
- 5.2.8 Melanoma
- 5.2.9 Sarcoma
- 5.2.10 Uterine cancer
- 5.2.11 Pancreatic cancer
- 5.2.12 Other hereditary cancers
- 5.3 Hereditary non-cancer testing
- 5.3.1 Genetic tests
- 5.3.1.1 Cardiac diseases
- 5.3.1.2 Rare diseases
- 5.3.1.3 Other diseases
- 5.3.2 Preimplantation genetic diagnosis & screening
- 5.3.3 Non-invasive prenatal testing (NIPT) & carrier screening tests
- 5.3.4 Newborn genetic screening
- 5.3.1 Genetic tests
Chapter 6 Market Estimates and Forecast, By Technology, 2021 – 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Cytogenetic
- 6.3 Biochemical
- 6.4 Molecular testing
Chapter 7 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
- 7.1 Key trends
- 7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 France
- 7.3.4 Spain
- 7.3.5 Italy
- 7.3.6 Netherlands
- 7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 South Korea
- 7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Mexico
- 7.5.3 Argentina
- 7.6 Middle East and Africa
- 7.6.1 South Africa
- 7.6.2 Saudi Arabia
- 7.6.3 UAE
Chapter 8 Company Profiles
- 8.1 Agilent Technologies
- 8.2 Centogene
- 8.3 CooperSurgical
- 8.4 F. Hoffmann-La Roche
- 8.5 Fulgent Genetics
- 8.6 Illumina
- 8.7 Invitae Corporation
- 8.8 Laboratory Corporation of America Holdings
- 8.9 MedGenome
- 8.10 Myriad Genetics
- 8.11 Natera
- 8.12 Quest Diagnostics
- 8.13 Sophia Genetics
- 8.14 Thermo Fisher Scientific
- 8.15 Twist Bioscience
